In vitro antibacterial activity of cefoxitin and cefotetan and pharmacokinetics in dogs.
The susceptibility of 50 clinical Escherichia coli isolates to various antibacterials, including cefoxitin and cefotetan was ascertained, and the minimal inhibitory concentration (MIC) of cefoxitin and cefotetan for each of these isolates was determined. The pharmacokinetics of cefoxitin and cefotetan after a single i.v. or SC injection (30 mg/kg of body weight) were determined in 4 dogs. Of the 50 E coli isolates, 98% were susceptible in vitro to cefotetan, 90% were susceptible to cefoxitin, and 88% were susceptible to gentamicin. The MIC that would inhibit the growth of 90% of the E coli isolates (MIC90) was 0.25 microgram/ml for cefotetan and 4 micrograms/ml for cefoxitin. Plasma cefotetan concentrations remained above MIC90 for (mean +/- SD) 8.2 +/- 1.72 hours and 13.52 +/- 0.28 hours after i.v. and SC administration, respectively. Plasma cefoxitin concentrations remained above MIC90 for (mean +/- SD) 5.37 +/- 1.18 hours and 7.95 +/- 0.71 hours after i.v. and SC administration, respectively. We concluded that cefotetan was superior to cefoxitin in activity against E coli in vitro. We recommend that cefotetan be given at a dosage of 30 mg/kg, i.v., every 8 hours, or SC, every 12 hours.
Petersen
S W
SW
Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison 53706.
Rosin
E
E
D000818:Animals; D015313:Cefotetan / Q000493:pharmacokinetics* / Q000494:pharmacology*; D002440:Cefoxitin / Q000493:pharmacokinetics* / Q000494:pharmacology*; D004285:Dogs; D004926:Escherichia coli / Q000187:drug effects*; D008297:Male; D008826:Microbial Sensitivity Tests / Q000662:veterinary
D015313:Cefotetan; D002440:Cefoxitin